A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain

A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain

GNF-2 is an allosteric inhibitor of Bcr-Abl. It was developed as a new class of anti-cancer drug to treat resistant chronic myelogenous leukemia. Recent studies suggest that c-Abl inhibition would provide a neuroprotective effect in animal models of Parkinson’s disease as well as in clinical trials....

Full description

Bibliographic Details
Main Authors: Gyun Jee Song, Md Habibur Rahman, Mithilesh Kumar Jha, Deepak Prasad Gupta, Sung Hee Park, Jae-Hong Kim, Sun-Hwa Lee, In-Kyu Lee, Taebo Sim, Yong Chul Bae, Won-Ha Lee, Kyoungho Suk
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-05-01
Series:Frontiers in Pharmacology
Subjects:
GNF-2
c-Abl
glia
neuroinflammation
pain
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00543/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00543/full

Similar Items